Table 3 Safety details according to patientsā€™ age.

From: Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients

Toxicity

ā€‰ā‰„ā€‰75Ā years, n (%)

ā€‰<ā€‰75Ā years, n (%)

Tot patients

Nā€‰=ā€‰112

Nā€‰=ā€‰472

Hematologic

27 (24.1)

93 (19.7)

Ā Ā Ā G1-2

18 (16.1)

66 (13.9)

Ā Ā Ā G3-4

9 (8.03)

27 (5.7)

Nausea/vomiting

15 (13.4)

90 (19.1)

Ā Ā Ā G1-2

12 (10.7)

81 (17.2)

Ā Ā Ā G3-4

3 (2.7)

9 (1.9)

Diarrhea

14 (12.5)

65 (13.8)

Ā Ā Ā G1-2

12 (10.7)

61 (12.9)

Ā Ā Ā G3-4

2 (1.8)

4 (0.8)

Fatigue

13 (11.6)

53 (11.2)

Ā Ā Ā G1-2

11 (9.8)

50 (10.6)

Ā Ā Ā G3-4

2 (1.8)

3 (0.6)

Cutaneous

8 (7.1)

60 (12.7)

Ā Ā Ā G1-2

7 (6.3)

47 (9.9)

Ā Ā Ā G3-4

1 (0.9)

13 (2.7)

Hepatic

5 (4.5)

38 (8.0)

Ā Ā Ā G1-2

3 (2.7)

32 (6.8)

Ā Ā Ā G3-4

2 (1.8)

6 (1.3)

Other toxicity

11 (9.8)

61 (12.9)

Ā Ā Ā G1-2

7 (63.6)

55 (90.2)

Ā Ā Ā G3-4

4 (36.4)

6 (9.8)

Back to article page